TY  - CHAP
M1  - Book, Section
TI  - Chapter 71. Lipodystrophy
A1  - Garg, Abhimanyu
A2  - Goldsmith, Lowell A.
A2  - Katz, Stephen I.
A2  - Gilchrest, Barbara A.
A2  - Paller, Amy S.
A2  - Leffell, David J.
A2  - Wolff, Klaus
PY  - 2012
T2  - Fitzpatrick's Dermatology in General Medicine, 8e
AB  - |PrintLipodystrophy  at  a  GlanceLipodystrophies  are  genetic  or  acquired  disorders  characterized  by  selective  loss  of  body  fat.  The  extent  of  fat  loss  determines  the  severity  of  associated  metabolic  complications  such  as  diabetes  mellitus,  hypertriglyceridemia,  hepatic  steatosis,  and  acanthosis  nigricans.Four  loci  have  been  identified  for  the  autosomal  recessive  congenital  generalized  lipodystrophy  (CGL),  namely,  (1)  AGPAT2,  (2)  BSCL2,  (3)  CAV1,  and  (4)  PTRF.Four  loci  have  been  identified  for  autosomal  dominant  familial  partial  lipodystrophy  (FPL),  namely,  (1)  LMNA,  (2)  PPARG,  (3)  AKT2,  and  (4)  PLIN1.CIDEC  is  the  locus  for  autosomal  recessive  FPL,  and  LMNA  and  ZMPSTE24  are  loci  for  autosomal  recessive  mandibuloacral  dysplasia-associated  lipodystrophy.Molecular  basis  of  many  rare  forms  of  genetic  lipodystrophies  remains  to  be  elucidated.The  most  prevalent  variety  of  lipodystrophy  develops  after  prolonged  duration  of  protease  inhibitor  containing  highly  active  antiretroviral  therapy  in  HIV-infected  patients.The  acquired  generalized  lipodystrophy  and  acquired  partial  lipodystrophy  are  mainly  autoimmune  in  origin.Localized  lipodystrophies  occur  due  to  drug  or  vaccine  injections,  pressure,  panniculitis,  and  other  unknown  reasons.The  current  management  includes  cosmetic  surgery  and  early  identification  and  treatment  of  metabolic  and  other  complications.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/16
UR  - accessmedicine.mhmedical.com/content.aspx?aid=56042058
ER  -